Improdia is Monitoring the Immune Status
- Fields of Activity : Life Sciences / Personalized Cancer Treatment / Diagnostics
- Product Type: Diagnostic Blood Test/Biomarkers Detection and Quantification
- The Product: A blood test monitoring the immune status of patients suffering from diseases associated with chronic Inflammation
- Senior Management: Miriam Lerner, Co-CEO & CTO; Dr. Raphael Nir, Founder; Prof. David Meiri, Chairman of Scientific Advisory Board; Dr. Roy Eldor, Medical Advisor; Prof. Michal Baniyash, Inventor; Monica Wolmer, CFO; Dr. Gil S. Pogozelich, Chairman.
- Key Stake Owners: Goldman Bio; Dr. Raphael Nir; Mr. Shamir Kaminisky; Citrine-8 Limited Partnership. Yissum Technology Transfer Company of the Hebrew University Ltd.
- More Info : https://improdia.co.il
- Company Synopsis | Hebrew Summary
- Follow us
A blood test that detects chronic inflammation, enabling precision therapy, monitoring and prognosis
Impaired immune system is one of the major side effects of various diseases associated with chronic inflammation such as diabetes, cancer, auto-immune and cardiovascular diseases. One of the most serious outcomes of chronic inflammation is the suppression of the immune system, therefore, there is a tremendous need for new tools to evaluate the immune status of those patients.
Current tests for measuring inflammation cannot distinguish between acute and chronic inflammation, unbaling to define the immune status of a patient, an important data needed by both physicians and pharmaceutical companies.
There is a need for new technologies to enable the monitoring of an individual’s immune status, and oversee disease regression, recurrence, treatment response and predict treatment outcome as well as identify possibility to have complications related the patients` immune status.
Improdia is developing a prognostic/diagnostic test, based on a research on innovative biomarkers conducted by Prof. Michal Baniyash from the Hebrew University of Jerusalem. The company’s core technology is based on measuring levels of its revolutionary biomarkers both cells (MDSCs) and proteins (CD247 & SNX9). It was demonstrated that MDSC levels are upregulated and CD247 & SNX9 are down-regulated in chronic inflammatory conditions, leading to immune dysfunction. Improdias` technology distinguish between acute and chronic inflammation, it was shown a high correlation between the presence of chronic inflammation and the progression of diseases such as Cancer, Diabetes and others. The uniqueness of these biomarkers and the fact that they hold different sensitivity to the inflammatory environment, can offer reliable and validated solutions for identifying chronic inflammation and impaired immune status associated with numerous diseases.
The test tracks the immune status of patients suffering from a variety of diseases associated with chronic inflammation to provide personalized treatment. The company is currently focused on predicting the effectiveness of immunotherapy cancer treatment when combined with the use of cannabis and predicting lethal complications for Diabetes patients.
The novel technology has enormous potential both as a prognostic/diagnostic test and as a key tool for pharmaceutical companies in the development of new drugs for a wide range of diseases associated with chronic inflammation such as Cancer, Heart, Rheumatology and Pulmonary diseases.
Improdias` simple blood test that gives quick and accurate results in real time, will help to identify patients who are most likely to be benefit from a particular therapeutic treatment and to predict the occurrence of complications before they are evident, allowing for personalized and efficient treatment for each patient according to their immune status.
The kit tracks the immune status of patients suffering from a variety of diseases associated with chronic inflammation. The company is currently focused on predicting the effectiveness of immunotherapy treatment when combined with cannabis, as well as on indication of possible complications in patients with diabetes.